retatrutide phase 2 nejm weight loss 48 weeks 2023 percent Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide produces up to 30.3%

Cytotoxicity assays confirm good biocompatibility up to 200 g/mL

Ferroptosis and human diseases The accumulation of excess iron serves as the primary catalyst for ferroptosis, thereby increasing the vulnerability of various cell types to this form of cell death [82]

any menstrual changes are more likely to be secondary to weight loss itself

L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector

Roches dual GLP-1/GIP receptor agonist candidate achieved 22.5% weight loss after nearly a year of treatment, setting the asset up for late-stage testing and a potential challenge to Eli Lillys mega-blockbuster obesity franchise